Pelvic Organ ProlapseNCT04087642
CREDE Study: Intraoperative Crede Manoeuver Compared to Preoperative Prolapse Reduction Stress Test to Predict Postoperative de Novo Stress Urinary Incontinence (PONSUI) at the Time of Pelvic Organ Prolapse (POP) Surgery
A study testing Intraoperative Crede manoeuver and Preoperative prolapse reduction cough stress test in people with Pelvic Organ Prolapse and de Novo Stress Urinary Incontinence, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 2 sites in Canada.
Trial summary
The CREDE pilot randomized study will compare the intraoperative Crede manoeuver (M1) to preoperative prolapse (POP) reduction cough stress test (M2) for the prediction and prevention of PONSUI. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Pelvic Organ Prolapse, de Novo Stress Urinary Incontinence, Stress Urinary Incontinence
- What is being tested?
- Intraoperative Crede manoeuver and Preoperative prolapse reduction cough stress test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 2 sitesCanada
- Study dates
- 1 Sep 2019to 11 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Anterior, uterine or apical prolapse with a POP-Q stage II or more requiring surgical correction
Who cannot join
- Stress urinary incontinence (SUI) on history
- Previous anti-incontinence surgery
- Pregnancy
- Prior urethral repair surgery (diverticulum, fistula)
- Women who do not speak or read English or French
- Isolated posterior compartment prolapse
- Geographic location preventing women to come to 6 week and 6 month appointments
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
St. Mary's Hospital
Montreal, Quebec, H3T1M5
McGill University Health Centre
Montreal, Quebec, H4A3J1
About this study
The CREDE pilot randomized study will compare the intraoperative Crede manoeuver (M1) to preoperative prolapse (POP) reduction cough stress test (M2) for the prediction and prevention of PONSUI. The rates of PONSUI and its effect on patient reported outcomes and quality of life will be determined among women with positive or negative tests, and those with and without concomitant anti-incontinence procedure performed. This information will help inform larger studies on the topic.
Read the detailed description
Primary objective
- To assess feasibility of a pilot study to test this hypothesis with the goal to conduct a full trial (sample size calculation, validation of instruments used, randomization processes)
- To estimate the rate of subjective PONSUI at 6 weeks and at 6 months in continent women undergoing POP surgical repair where a positive intraoperative Crede maneuver (M1) vs. a positive preoperative prolapse reduction stress test (M2) are used to select candidates for concomitant anti-incontinence procedure (either 1. retropubic midurethral sling (MUS) or 2. periurethral bulking injections)
Secondary objectives
- To compare the estimated rate of objective PONSUI at 6 weeks and at 6 months (as determined by cough stress test) in continent women undergoing POP surgical repair where a positive intraoperative Crede maneuver (M1) vs. a positive preoperative prolapse reduction stress test (M2) are used to select candidates for concomitant anti-incontinence procedure II. To compare the rate of urinary symptoms and the effect on quality of life at 6 weeks and 6 months between M1 and M2, by Urinary Distress Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7) III. To describe the risk of complications in patients having either maneuvers (M1, M2), including bladder perforation, voiding dysfunction, urinary tract infection and mesh exposure IV. To assess the concordance/discordance rate of M1 and M2 to compare the predictive subjective and objective PONSUI values of both maneuvers by test results and by anti-incontinence procedure
Methodology
This is a pilot randomized controlled study of two parallel groups, in a sample of 110 continent women undergoing surgical correction of symptomatic pelvic organ prolapse (POP). The sample will be drawn from women presenting to three urogynecologists at St-Mary's hospital and McGill University Health Center (MUHC).
Intervention:
The patients will be randomized in two groups, allocated in a 1:1 ratio. All participants will undergo both methods to evaluate their risk of PONSUI. Method 1 (M1) consists in intraoperative Crede maneuver. Method 2 (M2) consists in a preoperative prolapse reduction stress test. In group A: A positive M1 will determine performance of anti-incontinence procedure. In group B: A positive M2 will determine performance of anti-incontinence procedure.
Surgical Procedure In both groups, women will have their planned surgery for POP correction under spinal (regional) or general anesthesia. The POP repair followed by the M1 will be performed for all women. The result of preoperative M2 won't be available to surgeon at the moment of performing M1. If the PONSUI prediction test for which the patient had been randomized to is positive, we will perform the anti-incontinence procedure selected by the patient (1. retropubic midurethral sling (MUS), or 2. periurethral bulking injections) after the POP repair. Placement of MUS and periurethral bulking injections will follow standardized reported technique. After the surgical procedure, a Foley catheter or suprapubic catheter will be inserted, and removed on postoperative day one. After catheter removal, a trial of void protocol is in place at our institutions. If post void residual volume by bladder scanner is over 250 mL, the Foley catheter will be reinserted and left in place for one week (or the suprapubic catheter will be kept for one week), while prophylactic antibiotics are given.
Randomization:
To address potential imbalances across study groups a computer-generated (SAS version 9.4) randomization schedule will be stratified by surgeon (3-5 different surgeons) and type of incontinence procedure chose (1. MUS, 2. Bulking), using random block sizes of 2 or 4, with an allocation ratio of 1:1. In order to ensure allocation concealment, the research assistant will first verify eligibility and informed consent, and then assign a study ID to each participant. Prior to the surgical procedure, the research assistant will enter this information plus the surgeon and incontinence procedure type into an automated interface prepared by the statistician. The result of randomization will be available to the surgeon only in the operating room (OR), after both the preoperative M2 and the intraoperative M1 have been performed. Specifically, the primary surgeon will be blinded until immediately after the M1 is performed and the result is recorded. The research assistant will have left an envelope with the randomization group in the OR prior to the beginning of the procedure. This envelope will be opened after the M1 is performed. The result of M2 will also be available if the woman is randomized to group B.
Sample size consideration:
Approximately 200 patients undergo POP surgical repair surgery per year in the two centers where the study will be conducted. For the pilot study, we are planning to recruit 100 eligible patients (50 per group) into the study with an added 10% estimated dropout rate for an overall total of 110 patients (55 per group). To the best of our knowledge, no previous study exists which would allow us to perform the appropriate sample size calculations. To do so, we would need some estimate of the rate of subjective PONSUI after intraoperative Crede maneuver (M1) at 6 weeks and 6 months. It is one of the purposes of this pilot project to determine such a parameter for planning a future randomized controlled trial. The rate of subjective PONSUI after preoperative prolapse reduction stress test (M2) varies around 14%, 54%, 17%, 26% for positive tests with and without anti-incontinence surgery and for negative tests with and without anti-incontinence surgery respectively. We thus estimate an overall rate of 30% PONSUI with the use of the preoperative prolapse reduction stress test. In the absence of an educated guess, we have verified that with our sample size (50 in each group) the minimal significant difference of 22% (30% vs 8%) between two groups PONSUI rates could be detected with a power of at least 80% using Pearson chi-squared and a confidence level of α = 0.05. Also, a set of relevant baseline imbalances will be pre-specified (recruitment site and prolapse stage "II vs III-IV") and a stratified randomization will be performed.
Data gathering Variables collected will include age, medication (including hormonal therapy), smoking status, diabetes, past obstetrical history (including parity, vaginal deliveries and cesarean sections), previous surgery for POP (type), previous hysterectomy, menopausal status, daytime frequency and nocturia. Patient will also answer validated questionnaires on urinary symptoms and impact on quality of life including: 1. Urinary Distress Inventory (UDI-6), and 2. Urinary Impact Questionnaire (UIQ-7).
At baseline, physical examination will be performed by one of the three participating urogynecologists or one of the urogynecology fellows. It will include POP-Q evaluation, genitourinary atrophy assessment, myofascial pain (pain at palpation of the vaginal muscles), and the preoperative prolapse reduction stress test (M2) for all women (positive/negative). After the exam, women will be asked to urinate and we will estimate the post void residual volume (urine left into the bladder after a micturition) with a bladder scanner.
At the moment of the surgery to correct the POP, all of the women will have a Crede maneuver assessment (M1). The result of the test will be noted (positive/negative). Information collected at the time of the surgery will include date, type of surgery, type of anesthesia (general or regional), estimated blood loss, perioperative complications (as bladder and urethral perforation or hemorrhage). Postoperative complications such as postoperative urinary retention (use of Foley/suprapubic catheter for seven days or more), and urinary tract infection will also be recorded.
Women will follow the usual postoperative visit calendar used in our institutions (visit 6 weeks and 6 months after the surgery). They will fill the same two questionnaires (UDI-6 and UIQ-7) that they answered at the beginning of the study. A blinded urogynecologist or a fellow in urogynecology will perform an examination. The amount of urine into the bladder will be estimated with a bladder scanner. A cough stress test will be done with an amount estimated between 250-350 mL of urine. The patient will be asked to drink water if the bladder is not full enough. The women have to cough strongly while in supine position. The examiner will note if he sees urine leakage (positive test) or not (negative test). He/she will also do a vaginal examination to note prolapse stage (POP-Q), and if there are any complication including mesh erosion or extrusion and important pain.
The research assistant will be involved at the time of women's recruitment, to ensure patient randomization, to coordinate postoperative examinations by a blinded examiner, and for data collection.
- Being tested
- Intraoperative Crede manoeuver, Preoperative prolapse reduction cough stress test
- Medical subject headings
- Pelvic Organ Prolapse, Urinary Incontinence, Stress
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intraoperative Crede manoeuverDiagnostic test
In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
Preoperative prolapse reduction cough stress testDiagnostic test
In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
| Study group | Role | What they receive |
|---|---|---|
| Intraoperative Crede manoeuver | Experimental | Method 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak.
In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. Receives: Diagnostic Test: Intraoperative Crede manoeuver |
| Preoperative prolapse reduction cough stress test | Active comparator | An examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak.
In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. Receives: Diagnostic Test: Preoperative prolapse reduction cough stress test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective postoperative de novo stress urinary incontinence (PONSUI)
SUI occurring after a surgery (usually a prolapse correction) in a patient who did not have SUI before the surgery. In this study, PONSUI is defined as answering "yes" to question #3 in the UDI-6 questionnaire: "Do you experience urine leakage related to activity, coughing or sneezing?" after the surgery, in previously continent women.
Measured: 6 months
Secondary outcomes (5)
Objective PONSUI
Positive cough stress test
Measured: 6 months
Urinary symptoms
Scores on Urinary Distress Inventory (UDI-6)
Measured: 6 months
Complications
Perioperative and postoperative complications including: bladder perforation, voiding dysfunction, urinary tract infection and mesh exposure
Measured: 6 months
Prevalence and correlation of each test result
Percentage of positive tests and correlation between both tests
Measured: At baseline
Impact on quality of life
Urinary Impact Questionnaire (UIQ-7)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2019
- Study start1 Sep 2019
- Primary completion11 Mar 2025
- Study completion11 Mar 2025
Why it stopped: Prolonged slow recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pelvic Organ ProlapseStudies of the same condition, open and under way.
- More trials run by McGill University Health Centre/Research Institute of the McGill University Health CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Sponsor type
- University, hospital or other
- Collaborators
- St. Mary's Research Centre, Montreal
- Responsible party
- Principal investigator, Maryse Larouche, McGill University Health Centre/Research Institute of the McGill University Health Centre
- Investigators
- Maryse Larouche, MD, MPH, Principal investigator, St. Mary's Research Centre and RI-MUHC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04087642
- Sponsor's protocol ID
- MP-37-2019-4845
- Status last verified
- Oct 2026
- First submitted
- 4 Sep 2019
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CREDE Study: Intraoperative Crede Manoeuver Compared to Preoperative Prolapse Reduction Stress Test to Predict Postoperative de Novo Stress Urinary Incontinence (PONSUI) at the Time of Pelvic Organ Prolapse (POP) Surgery
- ClinicalTrials.gov ID
- NCT04087642
- Acronym / sponsor ID
- MP-37-2019-4845
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Prolonged slow recruitment
- Enrolment
- 25 participants (actual)
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreUniversity, hospital or other
- Collaborators
- St. Mary's Research Centre, Montreal
- Study start
- 1 Sep 2019 (actual)
- Primary completion
- 11 Mar 2025 (actual)
- Study completion
- 11 Mar 2025 (actual)
- First posted
- 12 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The CREDE pilot randomized study will compare the intraoperative Crede manoeuver (M1) to preoperative prolapse (POP) reduction cough stress test (M2) for the prediction and prevention of PONSUI. The rates of PONSUI and its effect on patient reported outcomes and quality of life will be determined among women with positive or negative tests, and those with and without concomitant anti-incontinence procedure performed. This information will help inform larger studies on the topic.
Detailed description
Primary objective
- To assess feasibility of a pilot study to test this hypothesis with the goal to conduct a full trial (sample size calculation, validation of instruments used, randomization processes)
- To estimate the rate of subjective PONSUI at 6 weeks and at 6 months in continent women undergoing POP surgical repair where a positive intraoperative Crede maneuver (M1) vs. a positive preoperative prolapse reduction stress test (M2) are used to select candidates for concomitant anti-incontinence procedure (either 1. retropubic midurethral sling (MUS) or 2. periurethral bulking injections)
Secondary objectives
- To compare the estimated rate of objective PONSUI at 6 weeks and at 6 months (as determined by cough stress test) in continent women undergoing POP surgical repair where a positive intraoperative Crede maneuver (M1) vs. a positive preoperative prolapse reduction stress test (M2) are used to select candidates for concomitant anti-incontinence procedure II. To compare the rate of urinary symptoms and the effect on quality of life at 6 weeks and 6 months between M1 and M2, by Urinary Distress Inventory (UDI-6) and Urinary Impact Questionnaire (UIQ-7) III. To describe the risk of complications in patients having either maneuvers (M1, M2), including bladder perforation, voiding dysfunction, urinary tract infection and mesh exposure IV. To assess the concordance/discordance rate of M1 and M2 to compare the predictive subjective and objective PONSUI values of both maneuvers by test results and by anti-incontinence procedure
Methodology
This is a pilot randomized controlled study of two parallel groups, in a sample of 110 continent women undergoing surgical correction of symptomatic pelvic organ prolapse (POP). The sample will be drawn from women presenting to three urogynecologists at St-Mary's hospital and McGill University Health Center (MUHC).
Intervention:
The patients will be randomized in two groups, allocated in a 1:1 ratio. All participants will undergo both methods to evaluate their risk of PONSUI. Method 1 (M1) consists in intraoperative Crede maneuver. Method 2 (M2) consists in a preoperative prolapse reduction stress test. In group A: A positive M1 will determine performance of anti-incontinence procedure. In group B: A positive M2 will determine performance of anti-incontinence procedure.
Surgical Procedure In both groups, women will have their planned surgery for POP correction under spinal (regional) or general anesthesia. The POP repair followed by the M1 will be performed for all women. The result of preoperative M2 won't be available to surgeon at the moment of performing M1. If the PONSUI prediction test for which the patient had been randomized to is positive, we will perform the anti-incontinence procedure selected by the patient (1. retropubic midurethral sling (MUS), or 2. periurethral bulking injections) after the POP repair. Placement of MUS and periurethral bulking injections will follow standardized reported technique. After the surgical procedure, a Foley catheter or suprapubic catheter will be inserted, and removed on postoperative day one. After catheter removal, a trial of void protocol is in place at our institutions. If post void residual volume by bladder scanner is over 250 mL, the Foley catheter will be reinserted and left in place for one week (or the suprapubic catheter will be kept for one week), while prophylactic antibiotics are given.
Randomization:
To address potential imbalances across study groups a computer-generated (SAS version 9.4) randomization schedule will be stratified by surgeon (3-5 different surgeons) and type of incontinence procedure chose (1. MUS, 2. Bulking), using random block sizes of 2 or 4, with an allocation ratio of 1:1. In order to ensure allocation concealment, the research assistant will first verify eligibility and informed consent, and then assign a study ID to each participant. Prior to the surgical procedure, the research assistant will enter this information plus the surgeon and incontinence procedure type into an automated interface prepared by the statistician. The result of randomization will be available to the surgeon only in the operating room (OR), after both the preoperative M2 and the intraoperative M1 have been performed. Specifically, the primary surgeon will be blinded until immediately after the M1 is performed and the result is recorded. The research assistant will have left an envelope with the randomization group in the OR prior to the beginning of the procedure. This envelope will be opened after the M1 is performed. The result of M2 will also be available if the woman is randomized to group B.
Sample size consideration:
Approximately 200 patients undergo POP surgical repair surgery per year in the two centers where the study will be conducted. For the pilot study, we are planning to recruit 100 eligible patients (50 per group) into the study with an added 10% estimated dropout rate for an overall total of 110 patients (55 per group). To the best of our knowledge, no previous study exists which would allow us to perform the appropriate sample size calculations. To do so, we would need some estimate of the rate of subjective PONSUI after intraoperative Crede maneuver (M1) at 6 weeks and 6 months. It is one of the purposes of this pilot project to determine such a parameter for planning a future randomized controlled trial. The rate of subjective PONSUI after preoperative prolapse reduction stress test (M2) varies around 14%, 54%, 17%, 26% for positive tests with and without anti-incontinence surgery and for negative tests with and without anti-incontinence surgery respectively. We thus estimate an overall rate of 30% PONSUI with the use of the preoperative prolapse reduction stress test. In the absence of an educated guess, we have verified that with our sample size (50 in each group) the minimal significant difference of 22% (30% vs 8%) between two groups PONSUI rates could be detected with a power of at least 80% using Pearson chi-squared and a confidence level of α = 0.05. Also, a set of relevant baseline imbalances will be pre-specified (recruitment site and prolapse stage "II vs III-IV") and a stratified randomization will be performed.
Data gathering Variables collected will include age, medication (including hormonal therapy), smoking status, diabetes, past obstetrical history (including parity, vaginal deliveries and cesarean sections), previous surgery for POP (type), previous hysterectomy, menopausal status, daytime frequency and nocturia. Patient will also answer validated questionnaires on urinary symptoms and impact on quality of life including: 1. Urinary Distress Inventory (UDI-6), and 2. Urinary Impact Questionnaire (UIQ-7).
At baseline, physical examination will be performed by one of the three participating urogynecologists or one of the urogynecology fellows. It will include POP-Q evaluation, genitourinary atrophy assessment, myofascial pain (pain at palpation of the vaginal muscles), and the preoperative prolapse reduction stress test (M2) for all women (positive/negative). After the exam, women will be asked to urinate and we will estimate the post void residual volume (urine left into the bladder after a micturition) with a bladder scanner.
At the moment of the surgery to correct the POP, all of the women will have a Crede maneuver assessment (M1). The result of the test will be noted (positive/negative). Information collected at the time of the surgery will include date, type of surgery, type of anesthesia (general or regional), estimated blood loss, perioperative complications (as bladder and urethral perforation or hemorrhage). Postoperative complications such as postoperative urinary retention (use of Foley/suprapubic catheter for seven days or more), and urinary tract infection will also be recorded.
Women will follow the usual postoperative visit calendar used in our institutions (visit 6 weeks and 6 months after the surgery). They will fill the same two questionnaires (UDI-6 and UIQ-7) that they answered at the beginning of the study. A blinded urogynecologist or a fellow in urogynecology will perform an examination. The amount of urine into the bladder will be estimated with a bladder scanner. A cough stress test will be done with an amount estimated between 250-350 mL of urine. The patient will be asked to drink water if the bladder is not full enough. The women have to cough strongly while in supine position. The examiner will note if he sees urine leakage (positive test) or not (negative test). He/she will also do a vaginal examination to note prolapse stage (POP-Q), and if there are any complication including mesh erosion or extrusion and important pain.
The research assistant will be involved at the time of women's recruitment, to ensure patient randomization, to coordinate postoperative examinations by a blinded examiner, and for data collection.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intraoperative Crede manoeuver | Experimental | Diagnostic Test: Intraoperative Crede manoeuverMethod 1 (M1) consists in intraoperative Crede maneuver: After POP surgical reduction, the bladder will be retrograde filled with 300 ml of sterile water through a catheter that will then be removed. Brief and forceful suprapubic pressure will be applied. The test is positive if the surgeon visualizes a urinary leak. In this group, the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. |
| Preoperative prolapse reduction cough stress test | Active comparator | Diagnostic Test: Preoperative prolapse reduction cough stress testAn examiner will perform the test preoperatively in the office, at the same visit as the recruitment. With a volume of 250-350 mL of urine in the bladder (confirmed by bladder scanner), a prolapse reduction cough stress test will be performed (posterior speculum blade for reduction). The test is positive if the examiner visualizes a urinary leak. In this group, the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Anterior, uterine or apical prolapse with a POP-Q stage II or more requiring surgical correction
Key exclusion criteria (7 listed)
- Stress urinary incontinence (SUI) on history
- Previous anti-incontinence surgery
- Pregnancy
- Prior urethral repair surgery (diverticulum, fistula)
- Women who do not speak or read English or French
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intraoperative Crede manoeuverIn this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed. | Diagnostic test | Intraoperative Crede manoeuver |
| Preoperative prolapse reduction cough stress testIn this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed. | Diagnostic test | Preoperative prolapse reduction cough stress test |
Primary outcome
Subjective postoperative de novo stress urinary incontinence (PONSUI)
Time frame: 6 months
SUI occurring after a surgery (usually a prolapse correction) in a patient who did not have SUI before the surgery. In this study, PONSUI is defined as answering "yes" to question #3 in the UDI-6 questionnaire: "Do you experience urine leakage related to activity, coughing or sneezing?" after the surgery, in previously continent women.
5 secondary outcomes
Objective PONSUI
Time frame: 6 months
Urinary symptoms
Time frame: 6 months
Complications
Time frame: 6 months
Prevalence and correlation of each test result
Time frame: At baseline
Impact on quality of life
Time frame: 6 months
Results and safety
The study was stopped early (reason given: Prolonged slow recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Pelvic Organ Prolapse
Recruiting
Safety and Performance of a Pelvic Floor Mesh Implant for Laparoscopic Sacrocolpopexy (ProGYNious)
Pelvic Organ Prolapse (POP), Synthetic Mesh
Active, not recruitingObservational study
i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)
Pelvic Organ Prolapse, Genital Prolapse
Recruiting
Pelvic Floor Muscle Training During Pregnancy
Urinary Incontinence, Anal Incontinence
Not yet recruiting
Perineal Protection Device for Reducing Perineal Trauma During Vaginal Delivery in First-time Mothers: a Multicenter Randomized Controlled Trial
Pelvic Floor Dysfunction, Perineal Laceration
Not yet recruitingPhase 4
Suzetrigine Following Urogynecologic Surgery: Investigation of Postoperative Pain Management
Pelvic Organ Prolapse (POP), Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maryse Larouche, MD, MPH principal investigator
St. Mary's Research Centre and RI-MUHC
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intraoperative Crede manoeuver and Preoperative prolapse reduction cough stress test in people with Pelvic Organ Prolapse and de Novo Stress Urinary Incontinence, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Prolonged slow recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective postoperative de novo stress urinary incontinence (PONSUI) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.